The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer

Abstract This study examined the health‐related quality of life (HRQoL) of patients with advanced non‐small cell lung cancer (NSCLC) receiving tislelizumab versus docetaxel in the open‐label, multicenter, Phase 3 trial called RATIONALE‐303 (NCT03358875). HRQoL was assessed with the EORTC QLQ‐C30, EO...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Dingzhi Huang, Caicun Zhou, Gisoo Barnes, Yiyuan Ma, Songzi Li, Lin Zhan, Boxiong Tang
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2023-08-01
Reeks:	Cancer Medicine
Onderwerpen:	docetaxel health‐related quality of life non‐small cell lung cancer patient‐reported outcomes programmed cell death protein‐1 inhibitor
Online toegang:	https://doi.org/10.1002/cam4.6361
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!